DBV Technologies posts results of Phase 3 Viaskin Peanut study
The REALISE study evaluated Viaskin Peanut 250 μg in 393 peanut-allergic children aged 4 to 11 years in a 6-month randomized, double-blind, placebo-controlled Phase III trial. The study began on October 25, 2016, with primary completion on September 22, 2017.
Primary source
ClinicalTrials.gov results record, October 8, 2026
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Read the source: Safety Study of Viaskin Peanut to Treat Peanut Allergy clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation